Sam Chun Dang Pharm. Co., Ltd (KOSDAQ:000250)
160,700
-6,500 (-3.89%)
Sep 11, 2026, 3:30 PM KST
Sam Chun Dang Pharm. Revenue
Sam Chun Dang Pharm. had revenue of 70.74B KRW in the quarter ending June 30, 2026, with 24.33% growth. This brings the company's revenue in the last twelve months to 259.90B, up 20.83% year-over-year. In the year 2025, Sam Chun Dang Pharm. had annual revenue of 231.81B with 9.90% growth.
Revenue (ttm)
259.90B
Revenue Growth
+20.83%
P/S Ratio
14.47
Revenue / Employee
614.42M
Employees
423
Market Cap
3.76T
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 231.81B | 20.88B | 9.90% |
| Dec 31, 2024 | 210.92B | 18.26B | 9.47% |
| Dec 31, 2023 | 192.67B | 15.33B | 8.65% |
| Dec 31, 2022 | 177.34B | 10.06B | 6.01% |
| Dec 31, 2021 | 167.27B | 412.57M | 0.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| BINEX | 157.28B |
| Oscotec | 144.18B |
| CG Invites | 30.11B |
| Mezzion Pharma | 8.43B |